Artelo Biosciences Stock Price

-0.01 (-0.39%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 24,445
Bid Price 2.44
Ask Price 2.56
News -
Day High 2.6001


52 Week Range


Day Low 2.52
Company Name Stock Ticker Symbol Market Type
Artelo Biosciences Inc ARTL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.39% 2.56 17:12:42
Open Price Low Price High Price Close Price Prev Close
2.59 2.52 2.6001 2.56 2.57
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
122 24,445 $ 2.58 $ 63,134 - 0.2599 - 7.20
Last Trade Time Type Quantity Stock Price Currency
16:00:01 35 $ 2.58 USD


Draw Mode:

Artelo Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.31M 2.86M 2.83M $ - $ - -6.00 -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 2.40k 33.00%

more financials information »

Artelo Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARTL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.592.692.4162.5214,180-0.03-1.16%
1 Month2.903.07492.382.6920,524-0.34-11.72%
3 Months3.764.322.383.3525,111-1.20-31.91%
6 Months0.33797.200.25993.40296,5712.22657.62%
1 Year0.59827.200.25991.14663,6751.96327.95%
3 Years2.427.200.25991.401,996,7290.145.79%
5 Years4.957.200.25991.401,742,907-2.39-48.28%

Artelo Biosciences Description

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.